Skip to search formSkip to main contentSkip to account menu

BN 50739

Known as: 4H-Pyrido(4',3':4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 6-(2-chlorophenyl)-9-(2-((3,4-dimethoxyphenyl)thio)-1-thioxoethyl)-7,8,9,10-tetrahydro-1-methyl-, BN-50739 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
The platelet-activating factor (PAF) antagonist BN-50739 can suppress certain cardiac arrhythmias. PAF is released from ischaemic… 
1997
1997
Abstract: The Pulsinelli‐Brierley four‐vessel occlusion model was used to study the consequences of hyperglycemic ischemia and… 
1997
1997
We investigated the mechanism of the hypotensive effect of Sar-[D-Phe8]des-Arg9-bradykinin (BK) in lipopolysaccharide-treated… 
1994
1994
Abstract: Recent evidence suggests that platelet‐activating factor plays a role in ischemia‐induced neural injury. The Pulsinelli… 
1992
1992
Interleukin-2 was recently shown to cause acute lung injury characterized by microvascular permeability defect, interstitial… 
1991
1991
STUDY OBJECTIVE The aim was to investigate the role of platelet activating factor (PAF) in myocardial ischaemia by using BN 50739… 
1990
1990
Platelet-activating factor (PAF) has been demonstrated in the circulation and organs of animals exposed to gram negative… 
Highly Cited
1990
Highly Cited
1990
BN 50739, a new PAF receptor antagonist, was tested in vitro and in vivo for its capacity to block PAF, endotoxin and recombinant…